virus strain, Adult, Male, demography, antibiotic resistance, Anti-HIV Agents, Human immunodeficiency virus 1, Antiretroviral Therapy, RNA directed DNA polymerase inhibitor, intravenous drug abuse, antiretrovirus agent; lamivudine; nelfinavir; RNA directed DNA polymerase inhibitor; adult; antibiotic resistance; article; clinical article; controlled study; demography; female; heterosexuality; highly active antiretroviral therapy; human; human cell; Human immunodeficiency virus 1; Human immunodeficiency virus infection; intravenous drug abuse; lymphocyte count; male; nonhuman; priority journal; risk factor; treatment outcome; virus load; virus mutation; virus replication; virus strain; virus typing; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV-1; Humans; Male; Treatment Outcome; Virus Replication, Settore MED/17 - MALATTIE INFETTIVE, Virus Replication, nelfinavir, male, Human immunodeficiency virus infection, Antiretroviral Therapy, Highly Active, Humans, controlled study, Highly Active, human, lymphocyte count, virus replication, clinical article, Acquired Immunodeficiency Syndrome, nonhuman, antiretrovirus agent, adult, human cell, virus mutation, article, Anti-HIV Agent, heterosexuality, highly active antiretroviral therapy, virus load, CD4 Lymphocyte Count, female, Treatment Outcome, priority journal, risk factor, treatment outcome, HIV-1, virus typing, Female, lamivudine